StockData
Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc. (AKBA) stock

AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.40−0.05 (-10.74%)

Close on Nov 17, 2026Market cap $110.95MP/E –Yield –

Akebia Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Akebia Therapeutics's price to book ratio was 6.2× on Nov 11, 2026, against 10.1× a year earlier. Over the last 5 years it ranged from 0.8× to 39.2×, with a median of 3.7×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20266.2×−4.0
2025Dec 31, 202510.3×−21.7
2023Apr 28, 202332.0×+19.1
2022Dec 30, 202212.9×+10.0
2021Dec 31, 20212.9×+1.6
2020Dec 31, 20201.3×−0.3
2019Dec 31, 20191.6×−0.6
2018Dec 31, 20182.2×−4.8
2017Dec 29, 20177.0×+3.1
2016Dec 30, 20164.0×+1.3
2015Dec 31, 20152.7×+0.6
2014Dec 31, 20142.1×–

More Akebia Therapeutics figures

See a number that looks wrong?